Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 7 (July)

1. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
   Br J Cancer, 101(1): 38-47. [Abstract] [Full-text]
2. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
   Br J Cancer, 101(1): 12-8. [Abstract] [Full-text]
3. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
   Chin J Integr Med, 15(3): 193-7. [Abstract] [Full-text]
4. Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels.
   J Am Chem Soc, 131(26): 9204-6. [Abstract] [Full-text]
5. Nursing student medication errors involving tubing and catheters: a descriptive study.
   Nurse Educ Today, 29(6): 681-8. [Abstract] [Full-text]
6. In vivo performance of a microelectrode neural probe with integrated drug delivery.
   Neurosurg Focus, 27(1): E8. [Abstract] [Full-text]
7. Borax mediated layer-by-layer self-assembly of neutral poly(vinyl alcohol) and chitosan.
   J Phys Chem B, 113(27): 9137-42. [Abstract] [Full-text]
8. Improved peptide prodrugs of 5-ALA for PDT: rationalization of cellular accumulation and protoporphyrin IX production by direct determination of cellular prodrug uptake and prodrug metabolization.
   J Med Chem, 52(13): 4026-37. [Abstract] [Full-text]
9. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial.
   J Am Coll Cardiol, 54(2): 118-26. [Abstract] [Full-text]
10. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy.
    Am J Gastroenterol, 104(7): 1707-14. [Abstract] [Full-text]
11. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model.
    Int J Cancer, 125(3): 698-707. [Abstract] [Full-text]
12. Restoration of XAF1 expression induces apoptosis and inhibits tumor growth in gastric cancer.
    Int J Cancer, 125(3): 688-97. [Abstract] [Full-text]
13. Preparation and characterization of a novel starch-based interpolyelectrolyte complex as matrix for controlled drug release.
    Carbohydr Res, 344(11): 1325-31. [Abstract] [Full-text]
14. Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy.
    Pharm Res, 26(8): 2027-36. [Abstract] [Full-text]
15. Drug delivery to the skin from sub-micron polymeric particle formulations: influence of particle size and polymer hydrophobicity.
    Pharm Res, 26(8): 1995-2001. [Abstract] [Full-text]
16. Fragmentation of molecule-induced gamma-cyclodextrin nanotubular suprastructures due to drug dosage.
    J Colloid Interface Sci, 337(1): 294-9. [Abstract] [Full-text]
17. Transfection by particle bombardment: delivery of plasmid DNA into mammalian cells using gene gun.
    Biochim Biophys Acta, 1790(8): 754-64. [Abstract] [Full-text]
18. Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy.
    Bone, 45(2): 246-53. [Abstract] [Full-text]
19. Evaluation of an electrolyte replacement protocol in an adult intensive care unit: a retrospective before and after analysis.
    Intensive Crit Care Nurs, 25(4): 181-9. [Abstract] [Full-text]
20. EEG under anesthesia--feature extraction with TESPAR.
    Comput Methods Programs Biomed, 95(3): 191-202. [Abstract] [Full-text]
21. Imidazole metalloporphyrins as photosensitizers for photodynamic therapy: role of molecular charge, central metal and hydroxyl radical production.
    Cancer Lett, 282(1): 63-76. [Abstract] [Full-text]
22. Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis.
    Int Urogynecol J Pelvic Floor Dysfunct, 20(8): 933-8. [Abstract] [Full-text]
23. Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin "Trojan Horse" antibiotics and synthetic desferridanoxamine-antibiotic conjugates.
    Biometals, 22(4): 633-48. [Abstract] [Full-text]
24. Siderophores as drug delivery agents: application of the "Trojan Horse" strategy.
    Biometals, 22(4): 615-24. [Abstract] [Full-text]
25. An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.
    Proc Natl Acad Sci U S A, 106(27): 11011-5. [Abstract] [Full-text]
26. Alprazolam prescribing in Tasmania: a two-fold intervention designed to reduce inappropriate prescribing and concomitant opiate prescription.
    Australas Psychiatry, 17(4): 300-5. [Abstract] [Full-text]
27. Hydrogen-bonded multilayer of pH-responsive polymeric micelles with tannic acid for surface drug delivery.
    Chem Commun (Camb). [Abstract] [Full-text]
28. Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database.
    J Clin Pharm Ther, 34(4): 377-86. [Abstract] [Full-text]
29. Appropriate prescribing in the elderly: an investigation of two screening tools, Beers criteria considering diagnosis and independent of diagnosis and improved prescribing in the elderly tool to identify inappropriate use of medicines in the elderly in primary care in Ireland.
    J Clin Pharm Ther, 34(4): 369-76. [Abstract] [Full-text]
30. Thermoresponsive core-shell magnetic nanoparticles for combined modalities of cancer therapy.
    Nanotechnology, 20(30): 305101. [Abstract] [Full-text]
31. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count.
    Vaccine, 27(34): 4731-8. [Abstract] [Full-text]
32. Diabetes and the menopause.
    Maturitas, 63(3): 200-3. [Abstract] [Full-text]
33. Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism.
    Nucl Med Commun, 30(8): 586-93. [Abstract] [Full-text]
34. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.
    Maturitas, 63(3): 213-9. [Abstract] [Full-text]
35. Menopause: knowledge, attitude and practice among Italian women.
    Maturitas, 63(3): 246-52. [Abstract] [Full-text]
36. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
    Anticancer Drugs, 20(7): 634-8. [Abstract] [Full-text]
37. Questioning the cardioprotective action of hormone replacement therapy in postmenopausal women.
    J Cardiovasc Med (Hagerstown), 10(8): 657-8. [Abstract] [Full-text]
38. Patterns of hormone therapy use in the Norwegian Women and Cancer study (NOWAC) 1996-2005.
    Maturitas, 63(3): 220-6. [Abstract] [Full-text]
39. Rates of serious infection after changes in regimens for medical abortion.
    N Engl J Med, 361(2): 145-51. [Abstract] [Full-text]
40. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.
    J Clin Invest, 119(7): 2086-99. [Abstract] [Full-text]
41. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
42. Antibiotic prophylaxis for leptospirosis.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
43. Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
44. Anti-angiogenic therapies for metastatic colorectal cancer.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
45. Adjuvant platinum-based chemotherapy for early stage cervical cancer.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
46. Thrombolytic therapy for pulmonary embolism.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
47. WITHDRAWN: Antibiotics for preventing leptospirosis.
    Cochrane Database Syst Rev. [Abstract] [Full-text]
48. Energetics investigation on encapsulation of protein/peptide drugs in carbon nanotubes.
    J Chem Phys, 131(1): 015101. [Abstract] [Full-text]
49. Synergistic drug combinations tend to improve therapeutically relevant selectivity.
    Nat Biotechnol, 27(7): 659-66. [Abstract] [Full-text]
50. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection.
    Clin Infect Dis, 49(3): 466-72. [Abstract] [Full-text]
51. Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies.
    Clin Infect Dis, 49(3): 473-6. [Abstract] [Full-text]
52. Cooperative and noncooperative binding of *Ru(bpy)3(2+) to DNA and SB4.5G dendrimers.
    J Phys Chem B, 113(28): 9373-8. [Abstract] [Full-text]
53. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.
    J Clin Oncol, 27(20): 3379-84. [Abstract] [Full-text]
54. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
    J Clin Oncol, 27(20): 3297-302. [Abstract] [Full-text]
55. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review.
    J Antimicrob Chemother, 64(2): 239-50. [Abstract] [Full-text]
56. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.
    J Clin Oncol, 27(20): 3277-83. [Abstract] [Full-text]
57. Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study.
    J Eur Acad Dermatol Venereol, 23(8): 891-5. [Abstract] [Full-text]
58. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    J Clin Oncol, 27(20): 3284-9. [Abstract] [Full-text]
59. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
    J Clin Oncol, 27(20): 3385-90. [Abstract] [Full-text]
60. Differences in prescription of narcotic pain medication after operative treatment of hip and ankle fractures in the United States and The Netherlands.
    J Trauma, 67(1): 160-4. [Abstract] [Full-text]
61. Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule.
    Oncology, 77(1): 63-70. [Abstract] [Full-text]
62. Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
    Oncology, 77(1): 49-52. [Abstract] [Full-text]
63. Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
    Oncology, 77(1): 40-8. [Abstract] [Full-text]
64. The effect of photodynamic therapy on tumor angiogenesis.
    Cell Mol Life Sci, 66(14): 2275-83. [Abstract] [Full-text]
65. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors.
    Cancer, 115(14): 3243-53. [Abstract] [Full-text]
66. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure.
    J Acquir Immune Defic Syndr, 51(4): 450-3. [Abstract] [Full-text]
67. "Click" glycodendrimers containing 27, 81, and 243 modified xylopyranoside termini.
    J Org Chem, 74(14): 5071-4. [Abstract] [Full-text]
68. A novel combination chemotherapy integrating with intratumoral chemotherapy.
    Med Hypotheses, 73(3): 334-5. [Abstract] [Full-text]
69. Prevention of orthogonal array of particles formation as a treatment approach for neuromyelitis optica.
    Med Hypotheses, 73(3): 361-2. [Abstract] [Full-text]
70. A robust, electrochemically driven microwell drug delivery system for controlled vasopressin release.
    Biomed Microdevices, 11(4): 861-7. [Abstract] [Full-text]
71. Flexible microfluidic devices supported by biodegradable insertion scaffolds for convection-enhanced neural drug delivery.
    Biomed Microdevices, 11(4): 915-24. [Abstract] [Full-text]
72. Does a novel prefilled injection device make postpartum oxytocin easier to administer? Results from midwives in Vietnam.
    Midwifery, 25(4): 461-5. [Abstract] [Full-text]
73. Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.
    Int J Clin Oncol, 14(3): 266-9. [Abstract] [Full-text]
74. Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC).
    Int J Clin Oncol, 14(3): 230-6. [Abstract] [Full-text]
75. Significance of volume-reduction surgery for far-advanced gastric cancer during treatment with novel anticancer agents.
    Int J Clin Oncol, 14(3): 225-9. [Abstract] [Full-text]
76. Comparation of liposomal formulations of ALA Undecanoyl ester for its use in photodynamic therapy.
    J Photochem Photobiol B, 96(2): 152-8. [Abstract] [Full-text]
77. Development of enzymatically cleavable prodrugs derived from dendritic polyglycerol.
    Bioorg Med Chem Lett, 19(14): 3725-8. [Abstract] [Full-text]
78. Virological and immunological stability in HIV infected patients undergoing partial-treatment interruption.
    J Clin Virol, 45(4): 362-6. [Abstract] [Full-text]
79. The robustness and flexibility of an emulsion solvent evaporation method to prepare pH-responsive microparticles.
    Int J Pharm, 377(1): 135-41. [Abstract] [Full-text]
80. Q10-loaded NLC versus nanoemulsions: stability, rheology and in vitro skin permeation.
    Int J Pharm, 377(1): 207-14. [Abstract] [Full-text]
81. Anti-inflammatory and anti-oxidant activity of anionic dendrimer-N-acetyl cysteine conjugates in activated microglial cells.
    Int J Pharm, 377(1): 159-68. [Abstract] [Full-text]
82. Double-layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol.
    Int J Pharm, 377(1): 128-34. [Abstract] [Full-text]
83. The universality of low-energy nano-emulsification.
    Int J Pharm, 377(1): 142-7. [Abstract] [Full-text]
84. Long-circulation of hemoglobin-loaded polymeric nanoparticles as oxygen carriers with modulated surface charges.
    Int J Pharm, 377(1): 199-206. [Abstract] [Full-text]
85. FG90 chitosan as a new polymer for metronidazole mucoadhesive tablets for vaginal administration.
    Int J Pharm, 377(1): 120-7. [Abstract] [Full-text]
86. Safety, tolerability and pharmacokinetics of phenoprolamine hydrochloride floating sustained-release tablets in healthy Chinese subjects.
    Int J Pharm, 377(1): 99-104. [Abstract] [Full-text]
87. Insulin-micro- and nanoparticles for pulmonary delivery.
    Int J Pharm, 377(1): 173-9. [Abstract] [Full-text]
88. Characterization and in vitro release of praziquantel from poly(epsilon-caprolactone) implants.
    Int J Pharm, 377(1): 112-9. [Abstract] [Full-text]
89. Quality by design approach to understand the process of nanosuspension preparation.
    Int J Pharm, 377(1): 185-98. [Abstract] [Full-text]
90. Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity.
    Int J Pharm, 377(1): 76-84. [Abstract] [Full-text]
91. Influence of nanocarrier type and size on skin delivery of hydrophilic agents.
    Int J Pharm, 377(1): 169-72. [Abstract] [Full-text]
92. Resin-supported catalytic dendrimers as multivalent artificial metallonucleases.
    Bioorg Med Chem Lett, 19(14): 3816-20. [Abstract] [Full-text]
93. Granule size control and targeting in pulsed spray fluid bed granulation.
    Int J Pharm, 377(1): 9-15. [Abstract] [Full-text]
94. Nanodispersions of taxifolin: impact of solid-state properties on dissolution behavior.
    Int J Pharm, 377(1): 148-52. [Abstract] [Full-text]
95. Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.
    Int J Pharm, 377(1): 1-8. [Abstract] [Full-text]
96. Enzymatic activation of hydrophobic self-immolative dendrimers: the effect of reporters with ionizable functional groups.
    Bioorg Med Chem Lett, 19(14): 3959-62. [Abstract] [Full-text]
97. Dendrimers ended by non-symmetrical azadiphosphonate groups: synthesis and immunological properties.
    Bioorg Med Chem Lett, 19(14): 3963-6. [Abstract] [Full-text]
98. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
    Eur J Nucl Med Mol Imaging, 36(8): 1226-34. [Abstract] [Full-text]
99. Isolated limb infusion: a review.
    J Surg Oncol, 100(2): 169-77. [Abstract] [Full-text]
100. Cisplatin-based chemotherapy followed by surgery for malignant nonseminomatous germ cell tumor of mediastinum: one institution's experience.
     Gen Thorac Cardiovasc Surg, 57(7): 363-8. [Abstract] [Full-text]
101. Hydrophilic multi-walled carbon nanotubes decorated with magnetite nanoparticles as lymphatic targeted drug delivery vehicles.
     Chem Commun (Camb). [Abstract] [Full-text]
102. Insulin pump therapy for type 1 diabetes treatment in a girl with Down's syndrome.
     Diabetes Res Clin Pract, 85(2): e16-8. [Abstract] [Full-text]
103. Independent mental health nurse prescribing.
     J Psychiatr Ment Health Nurs, 16(6): 508-15. [Abstract] [Full-text]
104. Tobacco smoking in individuals with attention-deficit hyperactivity disorder: epidemiology and pharmacological approaches to cessation.
     CNS Drugs, 23(8): 661-8. [Abstract] [Full-text]
105. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
     Schizophr Res, 113(1): 56-64. [Abstract] [Full-text]
106. The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel.
     Biomaterials, 30(25): 4161-7. [Abstract] [Full-text]
107. Chemoprevention of prostate cancer.
     J Urol, 182(2): 499-507; discussion 508. [Abstract] [Full-text]
108. Long-term improvements in insulin prescribing habits and glycaemic control in medical inpatients associated with the introduction of a standardized educational approach.
     Diabetes Res Clin Pract, 85(2): 159-65. [Abstract] [Full-text]
109. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
     Schizophr Res, 113(1): 19-26. [Abstract] [Full-text]
110. Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole.
     Chembiochem, 10(10): 1634-9. [Abstract] [Full-text]
111. Multifunctional hydroxyapatite nanofibers and microbelts as drug carriers.
     Chemistry, 15(28): 6973-82. [Abstract] [Full-text]
112. Interventions to improve medication adherence among older adults: meta-analysis of adherence outcomes among randomized controlled trials.
     Gerontologist, 49(4): 447-62. [Abstract] [Full-text]
113. Evaluation of the pulse pressure variation index as a predictor of fluid responsiveness during orthotopic liver transplantation.
     Br J Anaesth, 103(2): 238-43. [Abstract] [Full-text]
114. Controlled-release of rhBMP-2 carriers in the regeneration of osteonecrotic bone.
     Biomaterials, 30(25): 4178-86. [Abstract] [Full-text]
115. Layer-by-layer deposition of polymeric microgel films on surgical sutures for loading and release of ibuprofen.
     Langmuir, 25(14): 7990-4. [Abstract] [Full-text]
116. Self-assembled nanogel of hydrophobized dendritic dextrin for protein delivery.
     Macromol Biosci, 9(7): 694-701. [Abstract] [Full-text]
117. Injectable microsphere/hydrogel combination systems for localized protein delivery.
     Macromol Biosci, 9(7): 671-6. [Abstract] [Full-text]
118. PTH-analogs: comparable or different?
     Arch Gerontol Geriatr, 49(2): e130-2. [Abstract] [Full-text]
119. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
     Br J Cancer, 101(2): 263-8. [Abstract] [Full-text]
120. Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
     Br J Cancer, 101(2): 225-31. [Abstract] [Full-text]
121. Hormone therapy and ovarian cancer.
     JAMA, 302(3): 298-305. [Abstract] [Full-text]
122. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
     Br J Cancer, 101(2): 232-7. [Abstract] [Full-text]
123. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
     Br J Cancer, 101(2): 244-9. [Abstract] [Full-text]
124. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.
     Br J Cancer, 101(2): 238-43. [Abstract] [Full-text]
125. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
     Br J Cancer, 101(2): 219-24. [Abstract] [Full-text]
126. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
     Eur J Haematol, 83(2): 99-107. [Abstract] [Full-text]
127. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
     Mol Cancer Ther, 8(7): 1867-77. [Abstract] [Full-text]
128. Pharmacogenetics in heart failure: promises and challenges.
     Expert Opin Pharmacother, 10(11): 1713-25. [Abstract] [Full-text]
129. Synthesis and characterization of a carbon nanotube-dendron series for efficient siRNA delivery.
     J Am Chem Soc, 131(28): 9843-8. [Abstract] [Full-text]
130. Modeling the multivalent recognition between dendritic molecules and DNA: understanding how ligand "sacrifice" and screening can enhance binding.
     J Am Chem Soc, 131(28): 9686-94. [Abstract] [Full-text]
131. NFkappaB decoy delivery using dendritic poly(l-lysine) for treatment of endotoxin-induced hepatitis in mice.
     Bioorg Med Chem, 17(14): 4990-5. [Abstract] [Full-text]
132. Fluid replacement and heat stress during exercise alter post-exercise cardiac haemodynamics in endurance exercise-trained men.
     J Physiol, 587: 3605-17. [Abstract] [Full-text]
133. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
     Breast Cancer Res Treat, 116(3): 521-7. [Abstract] [Full-text]
134. Effects of 18 months of L-T4 replacement in women with subclinical hypothyroidism.
     Clin Endocrinol (Oxf), 71(2): 298-303. [Abstract] [Full-text]
135. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
     Breast Cancer Res Treat, 116(3): 509-20. [Abstract] [Full-text]
136. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.
     Breast Cancer Res Treat, 116(3): 491-500. [Abstract] [Full-text]
137. Intradialytic parenteral nutrition and intraperitoneal nutrition.
     Nutr Clin Pract, 24(4): 470-80. [Abstract] [Full-text]
138. The tissue-type plasminogen activator story.
     Arterioscler Thromb Vasc Biol, 29(8): 1151-5. [Abstract] [Full-text]
139. Development of an autonomous biological cell manipulator with single-cell electroporation and visual servoing capabilities.
     IEEE Trans Biomed Eng, 56(8): 2064-74. [Abstract] [Full-text]
140. Peri-operative oral triiodothyronine replacement therapy to prevent postoperative low triiodothyronine state following valvular heart surgery.
     Anaesthesia, 64(8): 871-7. [Abstract] [Full-text]
141. Sex differences in inappropriate drug use: a register-based study of over 600,000 older people.
     Ann Pharmacother, 43(7): 1233-8. [Abstract] [Full-text]
142. Ordering off the menu: assessing compliance with a nonformulary medication policy.
     Ann Pharmacother, 43(7): 1251-7. [Abstract] [Full-text]
143. Acquired Fanconi syndrome after treatment with capecitabine, irinotecan, and bevacizumab.
     Ann Pharmacother, 43(7): 1370-3. [Abstract] [Full-text]
144. Application of STOPP and START criteria: interrater reliability among pharmacists.
     Ann Pharmacother, 43(7): 1239-44. [Abstract] [Full-text]
145. Antiangiogenesis targeting tumor microenvironment synergizes glucuronide prodrug antitumor activity.
     Clin Cancer Res, 15(14): 4600-11. [Abstract] [Full-text]
146. 'Liberal' vs. 'restrictive' perioperative fluid therapy--a critical assessment of the evidence.
     Acta Anaesthesiol Scand, 53(7): 843-51. [Abstract] [Full-text]
147. Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo.
     J Med Chem, 52(14): 4306-18. [Abstract] [Full-text]
148. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
     Head Neck, 31(8): 1013-21. [Abstract] [Full-text]
149. Development of a novel pretargeting system with bifunctional nucleic acid molecules.
     Biochem Biophys Res Commun, 386(3): 521-5. [Abstract] [Full-text]
150. Cyclodextrins promote protein aggregation posing risks for therapeutic applications.
     Biochem Biophys Res Commun, 386(3): 526-31. [Abstract] [Full-text]
151. Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa.
     J Clin Oncol, 27(21): 3480-8. [Abstract] [Full-text]
152. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
     J Clin Oncol, 27(21): 3540-6. [Abstract] [Full-text]
153. Adjuvant hormonal therapy use among insured, low-income women with breast cancer.
     J Clin Oncol, 27(21): 3445-51. [Abstract] [Full-text]
154. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
     J Clin Oncol, 27(21): 3503-9. [Abstract] [Full-text]
155. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin.
     Ann Surg Oncol, 16(8): 2152-65. [Abstract] [Full-text]
156. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
     Ann Surg Oncol, 16(8): 2188-94. [Abstract] [Full-text]
157. Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth.
     Cancer Gene Ther, 16(8): 655-63. [Abstract] [Full-text]
158. Reassessment of the prognostic factors of international prognostic index (IPI) in the patients with diffuse large B-cell lymphoma in an era of R-CHOP in Chinese population.
     Ann Hematol, 88(9): 863-9. [Abstract] [Full-text]
159. Indications for thrombolysis in deep venous thrombosis.
     Eur J Vasc Endovasc Surg, 38(2): 192-8. [Abstract] [Full-text]
160. High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
     Int J Radiat Oncol Biol Phys, 74(5): 1522-8. [Abstract] [Full-text]
161. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
     Int J Radiat Oncol Biol Phys, 74(5): 1487-93. [Abstract] [Full-text]
162. Dramatic clearance of a recalcitrant acral viral wart using methyl aminolevulinate-red light photodynamic therapy.
     Photodermatol Photoimmunol Photomed, 25(4): 225-6. [Abstract] [Full-text]
163. A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin.
     Photodermatol Photoimmunol Photomed, 25(4): 191-5. [Abstract] [Full-text]
164. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
     Curr Med Res Opin, 25(8): 2081-90. [Abstract] [Full-text]
165. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis?
     Curr Med Res Opin, 25(8): 2021-41. [Abstract] [Full-text]
166. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK.
     Curr Med Res Opin, 25(8): 2007-19. [Abstract] [Full-text]
167. Folate-mediated chondroitin sulfate-Pluronic 127 nanogels as a drug carrier.
     Eur J Pharm Sci, 38(1): 64-73. [Abstract] [Full-text]
168. Dendrimer disassembly in the gas phase: a cascade fragmentation reaction of Fréchet dendrons.
     Chemistry, 15(29): 7139-49. [Abstract] [Full-text]
169. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial.
     Curr Med Res Opin, 25(8): 1853-60. [Abstract] [Full-text]
170. Photodynamic and sonodynamic treatment by phthalocyanine on cancer cell lines.
     Ultrasound Med Biol, 35(8): 1397-404. [Abstract] [Full-text]
171. Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio.
     Int J Androl, 32(4): 399-410. [Abstract] [Full-text]
172. Inorganic layered double hydroxides as ascorbic acid (vitamin C) delivery system--intercalation and their controlled release properties.
     Colloids Surf B Biointerfaces, 73(1): 103-9. [Abstract] [Full-text]
173. Role of alum in improving the immunogenicity of biodegradable polymer particle entrapped antigens.
     Eur J Pharm Sci, 38(1): 18-28. [Abstract] [Full-text]
174. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab.
     Pediatr Blood Cancer, 53(3): 392-6. [Abstract] [Full-text]
175. Effects of oral and transdermal estrogen therapies on circulating cytokines and chemokines in postmenopausal women with hysterectomy.
     Eur J Endocrinol, 161(2): 267-73. [Abstract] [Full-text]
176. Long-term hormone replacement therapy preserves bone mineral density in Turner syndrome.
     Eur J Endocrinol, 161(2): 251-7. [Abstract] [Full-text]
177. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead.
     J Control Release, 138(1): 2-15. [Abstract] [Full-text]
178. Parameters affecting organization and transfection efficiency of amphiphilic copolymers/DNA carriers.
     J Control Release, 138(1): 71-7. [Abstract] [Full-text]
179. Lysine-based peptide-functionalized PLGA foams for controlled DNA delivery.
     J Control Release, 138(1): 64-70. [Abstract] [Full-text]
180. Preparation and characterization of protein loaded microspheres based on a hydroxylated aliphatic polyester, poly(lactic-co-hydroxymethyl glycolic acid).
     J Control Release, 138(1): 57-63. [Abstract] [Full-text]
181. Studying the effectiveness of penetration enhancers to deliver retinol through the stratum cornum by in vivo confocal Raman spectroscopy.
     J Control Release, 138(1): 32-9. [Abstract] [Full-text]
182. Effects of intravenous and inhaled levosimendan in severe rodent sepsis.
     Intensive Care Med, 35(8): 1412-9. [Abstract] [Full-text]
183. Impact of shock requiring norepinephrine on the accuracy and reliability of subcutaneous continuous glucose monitoring.
     Intensive Care Med, 35(8): 1383-9. [Abstract] [Full-text]
184. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
     BJU Int, 104(3): 310-4. [Abstract] [Full-text]
185. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
     BJU Int, 104(3): 340-6. [Abstract] [Full-text]
186. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.
     BJU Int, 104(3): 336-9. [Abstract] [Full-text]
187. Hyperglycemia during acute coronary syndrome: a nurse-managed insulin infusion protocol for stricter and safer control.
     Eur J Cardiovasc Nurs, 8(3): 182-9. [Abstract] [Full-text]
188. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era.
     PLoS One, 4(7): e6328. [Abstract] [Full-text]
189. Prospective five-year study of ultrasound-guided foam sclerotherapy in the treatment of great saphenous vein reflux.
     Phlebology, 24(4): 183-8. [Abstract] [Full-text]
190. Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases.
     Phlebology, 24(4): 176-82. [Abstract] [Full-text]
191. Assessment of quality of life in Mexican patients suffering from chronic venous disorder - impact of oral Ruscus aculeatus-hesperidin-methyl-chalcone-ascorbic acid treatment - 'QUALITY Study'.
     Phlebology, 24(4): 157-65. [Abstract] [Full-text]
192. Changes in venous function after foam sclerotherapy of varicose veins.
     Phlebology, 24(4): 145-50. [Abstract] [Full-text]
193. Synthetic matrix containing glucocorticoid and growth factor for chondrogenic differentiation of stem cells.
     J Biosci Bioeng, 108(2): 168-73. [Abstract] [Full-text]
194. Systematic syntheses of influenza neuraminidase inhibitors: a series of carbosilane dendrimers uniformly functionalized with thioglycoside-type sialic acid moieties.
     Bioorg Med Chem, 17(15): 5451-64. [Abstract] [Full-text]
195. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.
     Clin Infect Dis, 49(4): 626-35. [Abstract] [Full-text]
196. Pharmacotherapy of sarcoma.
     Expert Opin Pharmacother, 10(12): 1953-63. [Abstract] [Full-text]
197. Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery.
     Acc Chem Res, 42(7): 881-92. [Abstract] [Full-text]
198. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
     Int J Cancer, 125(6): 1454-63. [Abstract] [Full-text]
199. Regulation of HSP70 on activating macrophages using PDT-induced apoptotic cells.
     Int J Cancer, 125(6): 1380-9. [Abstract] [Full-text]
200. Antiandrogenic activities of Glycyrrhiza glabra in male rats.
     Int J Androl, 32(4): 417-22. [Abstract] [Full-text]
201. Pharmacotherapy of cerebral ischemia.
     Expert Opin Pharmacother, 10(12): 1895-906. [Abstract] [Full-text]
202. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.
     J Pharmacol Exp Ther, 330(2): 377-88. [Abstract] [Full-text]
203. Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring.
     J Pharmacol Exp Ther, 330(2): 520-5. [Abstract] [Full-text]
204. Rats self-administer intravenous nicotine delivered in a novel smoking-relevant procedure: effects of dopamine antagonists.
     J Pharmacol Exp Ther, 330(2): 633-40. [Abstract] [Full-text]
205. Antibiotic prophylaxis improves Ureaplasma-associated lung disease in suckling mice.
     Pediatr Res, 66(2): 197-202. [Abstract] [Full-text]
206. Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone.
     Exp Eye Res, 89(2): 238-45. [Abstract] [Full-text]
207. Cell death pathways--potential therapeutic targets.
     Xenobiotica, 39(8): 616-24. [Abstract] [Full-text]
208. Dendritic chain reaction.
     J Am Chem Soc, 131(29): 9934-6. [Abstract] [Full-text]
209. Anxiety and pain during dental injections.
     J Dent, 37(9): 700-4. [Abstract] [Full-text]
210. Nanotechnological applications for the treatment of neurodegenerative disorders.
     Prog Neurobiol, 88(4): 272-85. [Abstract] [Full-text]
211. Estrogen replacement increases matrix metalloproteinase contribution to vasoconstriction in a rat model of menopause.
     J Hypertens, 27(8): 1602-8. [Abstract] [Full-text]
212. Serum myeloperoxidase level predicts reperfusion in patients with myocardial infarction receiving thrombolytic therapy.
     Heart Vessels, 24(4): 247-53. [Abstract] [Full-text]
213. Refractive and topographic results of transepithelial cross-linking treatment in eyes with intacs.
     Cornea, 28(7): 719-23. [Abstract] [Full-text]
214. One-year outcomes of repeated adjunctive photodynamic therapy during periodontal maintenance: a proof-of-principle randomized-controlled clinical trial.
     J Clin Periodontol, 36(8): 661-6. [Abstract] [Full-text]
215. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
     J Immunother, 32(7): 703-12. [Abstract] [Full-text]
216. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
     J Immunother, 32(7): 765-72. [Abstract] [Full-text]
217. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
     Br J Haematol, 146(3): 282-91. [Abstract] [Full-text]
218. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
     Br J Haematol, 146(3): 292-9. [Abstract] [Full-text]
219. Increased incidence of leprosy following HAART initiation: a manifestation of the immune reconstitution disease.
     AIDS, 23(12): 1599-600. [Abstract] [Full-text]
220. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients.
     Pharmacogenomics J, 9(4): 265-73. [Abstract] [Full-text]
221. Photodynamic therapy as an adjunct to systemic treatment in a case with unilateral presumed vascularized choroidal tuberculous granuloma.
     Int Ophthalmol, 29(4): 293-6. [Abstract] [Full-text]
222. Knockout rats via embryo microinjection of zinc-finger nucleases.
     Science, 325(5939): 433. [Abstract] [Full-text]
223. Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy.
     Surgery, 146(2): 269-73. [Abstract] [Full-text]
224. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
     Surgery, 146(2): 241-9. [Abstract] [Full-text]
225. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke.
     BMC Neurosci, 10: 79. [Abstract] [Full-text]
226. Intravenous infusion tests have limited utility for selecting long-term drug therapy in patients with chronic pain: a systematic review.
     Anesthesiology, 111(2): 416-31. [Abstract] [Full-text]
227. Pharmacokinetics and dosage adjustment in patients with renal dysfunction.
     Eur J Clin Pharmacol, 65(8): 757-73. [Abstract] [Full-text]
228. Drug prescriptions to outpatient children: a review of the literature.
     Eur J Clin Pharmacol, 65(8): 749-55. [Abstract] [Full-text]
229. Bacterial meningitis in HIV-1-infected patients in the era of highly active antiretroviral therapy.
     J Acquir Immune Defic Syndr, 51(5): 582-7. [Abstract] [Full-text]
230. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
     J Acquir Immune Defic Syndr, 51(5): 522-9. [Abstract] [Full-text]
231. Repeated large-volume epidural blood patches for the treatment of spontaneous intracranial hypotension.
     Can J Anaesth, 56(8): 609-13. [Abstract] [Full-text]
232. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean.
     J Acquir Immune Defic Syndr, 51(5): 615-23. [Abstract] [Full-text]
233. Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil.
     J Acquir Immune Defic Syndr, 51(5): 624-30. [Abstract] [Full-text]
234. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery.
     Int J Antimicrob Agents, 34(3): 231-5. [Abstract] [Full-text]
235. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database.
     Eur J Clin Pharmacol, 65(8): 839-46. [Abstract] [Full-text]
236. Prescription drugs among pregnant women in Lome, Togo, West Africa.
     Eur J Clin Pharmacol, 65(8): 831-8. [Abstract] [Full-text]
237. Medical treatment of pulmonary arterial hypertension.
     Semin Respir Crit Care Med, 30(4): 484-92. [Abstract] [Full-text]
238. Pulmonary arterial hypertension in congenital heart diseases.
     Semin Respir Crit Care Med, 30(4): 421-8. [Abstract] [Full-text]
239. Polymeric plant-derived excipients in drug delivery.
     Molecules, 14(7): 2602-20. [Abstract] [Full-text]
240. Novel biodegradable polyesters. Synthesis and application as drug carriers for the preparation of raloxifene HCl loaded nanoparticles.
     Molecules, 14(7): 2410-30. [Abstract] [Full-text]
241. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
     J Thorac Oncol, 4(8): 1002-9. [Abstract] [Full-text]
242. Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.
     J Thorac Oncol, 4(8): 969-75. [Abstract] [Full-text]
243. Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results).
     Ann Thorac Surg, 88(2): 385-90; discussion 390-1. [Abstract] [Full-text]
244. Complication and failure rates after corneal crosslinking.
     J Cataract Refract Surg, 35(8): 1358-62. [Abstract] [Full-text]
245. Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01).
     Radiat Oncol, 4: 23. [Abstract] [Full-text]
246. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer.
     J Thorac Oncol, 4(8): 983-7. [Abstract] [Full-text]
247. Medical negligence in drug associated deaths.
     Forensic Sci Int, 190(1): 67-73. [Abstract] [Full-text]
248. Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
     J Thorac Oncol, 4(8): 988-93. [Abstract] [Full-text]
249. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia.
     J Thorac Oncol, 4(8): 1010-6. [Abstract] [Full-text]
250. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
     J Thorac Oncol, 4(8): 1017-21. [Abstract] [Full-text]
251. Oral delivery of siRNA and antisense oligonucleotides.
     J Drug Target, 17(7): 491-5. [Abstract] [Full-text]
252. Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium.
     J Drug Target, 17(7): 543-52. [Abstract] [Full-text]
253. Pulmonary toxicity and kinetic study of Cy5.5-conjugated superparamagnetic iron oxide nanoparticles by optical imaging.
     Toxicol Appl Pharmacol, 239(1): 106-15. [Abstract] [Full-text]
254. Characterization of cationic liposomes having IL-2 expressed on their external surface, and their affinity to cervical cancer cells expressing the IL-2 receptor.
     J Drug Target, 17(7): 496-501. [Abstract] [Full-text]
255. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
     Cancer, 115(15): 3501-11. [Abstract] [Full-text]
256. Bcl-2 inhibitor HA14-1 and genistein together adeptly down regulated survival factors and activated cysteine proteases for apoptosis in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells.
     Brain Res, 1283: 155-66. [Abstract] [Full-text]
257. Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone.
     J Steroid Biochem Mol Biol, 116(3): 187-90. [Abstract] [Full-text]
258. Joint BAPEN and Nutrition Society Symposium on 'Feeding size 0: the science of starvation'. Severe malnutrition: therapeutic challenges and treatment of hypovolaemic shock.
     Proc Nutr Soc, 68(3): 274-80. [Abstract] [Full-text]
259. Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas: a single-center experience.
     Cancer, 115(15): 3392-9. [Abstract] [Full-text]
260. Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer.
     Radiother Oncol, 92(2): 226-30. [Abstract] [Full-text]
261. Hormone exposure and functional lateralisation: examining the contributions of prenatal and later life hormonal exposure.
     Psychoneuroendocrinology, 34(8): 1214-21. [Abstract] [Full-text]
262. Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model.
     Br J Ophthalmol, 93(8): 1105-8. [Abstract] [Full-text]
263. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021).
     Radiother Oncol, 92(2): 260-5. [Abstract] [Full-text]
264. Intravenous therapy for hypertensive emergencies, part 1.
     Am J Health Syst Pharm, 66(15): 1343-52. [Abstract] [Full-text]
265. pHLIP-mediated translocation of membrane-impermeable molecules into cells.
     Chem Biol, 16(7): 754-62. [Abstract] [Full-text]
266. Antegrade enemas for defecation disorders: do they improve the colonic motility?
     J Pediatr Surg, 44(8): 1575-80. [Abstract] [Full-text]
267. Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
     Radiat Oncol, 4: 24. [Abstract] [Full-text]
268. Avoiding "pseudo-reversibility" of CT-CBV infarct core lesions in acute stroke patients after thrombolytic therapy: the need for algorithmically "delay-corrected" CT perfusion map postprocessing software.
     Stroke, 40(8): 2875-8. [Abstract] [Full-text]
269. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS.
     Stroke, 40(8): 2743-8. [Abstract] [Full-text]
270. Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke.
     Stroke, 40(8): 2899-905. [Abstract] [Full-text]
271. Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET).
     Stroke, 40(8): 2872-4. [Abstract] [Full-text]
272. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
     Cancer Invest, 27(7): 756-63. [Abstract] [Full-text]
273. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
     Eur J Cancer, 45(12): 2116-22. [Abstract] [Full-text]
274. Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.
     Eur J Cancer, 45(12): 2132-7. [Abstract] [Full-text]
275. Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy.
     Cancer Invest, 27(7): 741-6. [Abstract] [Full-text]
276. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
     Eur J Cancer, 45(12): 2150-9. [Abstract] [Full-text]
277. Self-aggregation of water-soluble chitosan and solubilization of thymol as an antimicrobial agent.
     J Biomed Mater Res A, 90(3): 874-81. [Abstract] [Full-text]
278. International Society for Aerosols in Medicine, 17th congress, 10-14 May 2009, Monterey, California, USA.
     Expert Opin Drug Deliv, 6(8): 879-82. [Abstract] [Full-text]
279. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy.
     Expert Opin Drug Deliv, 6(8): 865-78. [Abstract] [Full-text]
280. Surface modified poly(amido)amine dendrimers as diverse nanomolecules for biomedical applications.
     Expert Opin Drug Deliv, 6(8): 835-50. [Abstract] [Full-text]
281. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
     Pharmacotherapy, 29(8): 993-6. [Abstract] [Full-text]
282. Frequency and severity of harm of medication errors related to the parenteral nutrition process in a large university teaching hospital.
     Pharmacotherapy, 29(8): 966-74. [Abstract] [Full-text]
283. Vesicular carriers for dermal drug delivery.
     Expert Opin Drug Deliv, 6(8): 813-25. [Abstract] [Full-text]
284. Targeting anti-HIV drugs to the CNS.
     Expert Opin Drug Deliv, 6(8): 771-84. [Abstract] [Full-text]
285. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies.
     Expert Opin Drug Deliv, 6(8): 785-92. [Abstract] [Full-text]
286. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.
     Expert Opin Drug Deliv, 6(8): 793-811. [Abstract] [Full-text]
287. Degradable polyethylenimines as DNA and small interfering RNA carriers.
     Expert Opin Drug Deliv, 6(8): 827-34. [Abstract] [Full-text]
288. Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus.
     Am J Hypertens, 22(8): 828-34. [Abstract] [Full-text]
289. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
     Laryngoscope, 119(8): 1510-7. [Abstract] [Full-text]
290. Optimization of the transient transformation of Catharanthus roseus cells by particle bombardment and its application to the subcellular localization of hydroxymethylbutenyl 4-diphosphate synthase and geraniol 10-hydroxylase.
     Plant Cell Rep, 28(8): 1215-34. [Abstract] [Full-text]
291. Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes.
     Diabetes Care, 32(8): 1437-9. [Abstract] [Full-text]
292. Integration of complementary medical treatments with rehabilitation from the perspectives of patients and their caregivers: a qualitative inquiry.
     Clin Rehabil, 23(8): 730-40. [Abstract] [Full-text]
293. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial.
     Diabetes Care, 32(8): 1372-7. [Abstract] [Full-text]
294. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization.
     Invest Ophthalmol Vis Sci, 50(8): 3890-6. [Abstract] [Full-text]
295. A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.
     Cancer Chemother Pharmacol, 64(4): 763-8. [Abstract] [Full-text]
296. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
     Cancer Chemother Pharmacol, 64(4): 673-80. [Abstract] [Full-text]
297. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
     Cancer Chemother Pharmacol, 64(4): 657-63. [Abstract] [Full-text]
298. A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
     Cancer Chemother Pharmacol, 64(4): 785-91. [Abstract] [Full-text]
299. Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
     Cancer Chemother Pharmacol, 64(4): 707-13. [Abstract] [Full-text]
300. An investigation into effects of in vitro test condition on the release properties of theophylline from HPMC matrices using factorial design.
     Arch Pharm Res, 32(7): 1087-96. [Abstract] [Full-text]
301. Enhanced transfection of polyplexes based on pluronic-polypropylenimine dendrimer for gene transfer.
     Arch Pharm Res, 32(7): 1045-54. [Abstract] [Full-text]
302. Micromeritics and release behaviours of cellulose acetate butyrate microspheres containing theophylline prepared by emulsion solvent evaporation and emulsion non-solvent addition method.
     Arch Pharm Res, 32(7): 1019-28. [Abstract] [Full-text]
303. Natural anti-inflammatory compounds for the management and adjuvant therapy of inflammatory bowel disease and its drug delivery system.
     Arch Pharm Res, 32(7): 997-1004. [Abstract] [Full-text]
304. Intravenous fluid restriction after major abdominal surgery: a randomized blinded clinical trial.
     Trials, 10: 50. [Abstract] [Full-text]
305. Beneficial effects of a combination of Korean red ginseng and highly active antiretroviral therapy in human immunodeficiency virus type 1-infected patients.
     Clin Vaccine Immunol, 16(8): 1127-31. [Abstract] [Full-text]
306. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs.
     J Cancer Res Clin Oncol, 135(9): 1137-48. [Abstract] [Full-text]
307. Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients.
     Jpn J Clin Oncol, 39(8): 514-22. [Abstract] [Full-text]
308. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients.
     Jpn J Clin Oncol, 39(8): 478-83. [Abstract] [Full-text]
309. A case report of pathologically complete response of a huge rectal cancer after systemic chemotherapy with mFOLFOX6.
     Jpn J Clin Oncol, 39(8): 528-33. [Abstract] [Full-text]
310. The relationship between computerized physician order entry and pediatric adverse drug events: a nested matched case-control study.
     Pharmacoepidemiol Drug Saf, 18(8): 751-5. [Abstract] [Full-text]
311. Patterns of medication use in the immigrant population resident in Spain: associated factors.
     Pharmacoepidemiol Drug Saf, 18(8): 743-50. [Abstract] [Full-text]
312. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
     Jpn J Clin Oncol, 39(8): 484-90. [Abstract] [Full-text]
313. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy.
     J Cancer Res Clin Oncol, 135(9): 1239-44. [Abstract] [Full-text]
314. Efficacy of antiretroviral therapy program in children in India: prognostic factors and survival analysis.
     J Trop Pediatr, 55(4): 225-32. [Abstract] [Full-text]
315. Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer.
     Nat Rev Clin Oncol, 6(8): 488-92. [Abstract] [Full-text]
316. Protective effect of topical antibiotics in breast augmentation.
     Plast Reconstr Surg, 124(2): 629-34. [Abstract] [Full-text]
317. Preparation and integration of human amnion nerve conduits using a light-activated technique.
     Plast Reconstr Surg, 124(2): 428-37. [Abstract] [Full-text]
318. Percutaneous treatment of lymphatic malformations.
     Otolaryngol Head Neck Surg, 141(2): 219-24. [Abstract] [Full-text]
319. Dual targeting of a thermosensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release.
     Nanotechnology, 20(33): 335101. [Abstract] [Full-text]
320. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
     Oncologist, 14(7): 683-94. [Abstract] [Full-text]
321. The future of targeted therapies in ovarian cancer.
     Oncologist, 14(7): 706-16. [Abstract] [Full-text]
322. Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia.
     J Clin Oncol, 27(22): 3698-704. [Abstract] [Full-text]
323. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
     J Clin Oncol, 27(22): 3684-90. [Abstract] [Full-text]
324. Modern trends in fluid therapy for burns.
     Burns, 35(6): 757-67. [Abstract] [Full-text]
325. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.
     J Clin Oncol, 27(22): 3677-83. [Abstract] [Full-text]
326. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
     J Clin Oncol, 27(22): 3664-70. [Abstract] [Full-text]
327. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.
     Mod Pathol, 22(8): 1094-101. [Abstract] [Full-text]
328. The value of combined soft-tissue and vessel visualisation before transarterial chemoembolisation of the liver using C-arm computed tomography.
     Eur Radiol, 19(9): 2302-9. [Abstract] [Full-text]
329. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response.
     Blood, 114(5): 1053-62. [Abstract] [Full-text]
330. Penumbra Stroke System as an "add-on" for the treatment of large vessel occlusive disease following thrombolysis: first results.
     Eur Radiol, 19(9): 2286-93. [Abstract] [Full-text]
331. Towards modeling of cardiac micro-structure with catheter-based confocal microscopy: a novel approach for dye delivery and tissue characterization.
     IEEE Trans Med Imaging, 28(8): 1156-64. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.